Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients.

Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudié H, Tanga V, Allégra M, Lespinet-Fabre V, Bordone O, Bonnetaud C, Schiappa R, Butori C, Bence C, Lacour JP, Hofman V, Hofman P.

Oncotarget. 2018 Nov 16;9(90):36238-36249. doi: 10.18632/oncotarget.26343. eCollection 2018 Nov 16.

2.

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.

Ilié M, Ngo-Mai M, Long-Mira E, Lassalle S, Butori C, Bence C, Hamila M, Hofman V, Hofman P.

J Vis Exp. 2018 Sep 25;(139). doi: 10.3791/58082.

PMID:
30320751
3.

Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma.

Ilié M, Beaulande M, Ben Hadj S, Chamorey E, Schiappa R, Long-Mira E, Lassalle S, Butori C, Cohen C, Leroy S, Guérin O, Mouroux J, Marquette CH, Pomerol JF, Erb G, Hofman V, Hofman P.

Cancers (Basel). 2018 Sep 13;10(9). pii: E326. doi: 10.3390/cancers10090326.

4.

New variant of necklace fibres display peculiar lysosomal structures and mitophagy.

Rinnenthal JL, Dittmayer C, Irlbacher K, Wacker I, Schröder R, Goebel HH, Butori C, Villa L, Sacconi S, Stenzel W.

Neuromuscul Disord. 2018 Oct;28(10):846-856. doi: 10.1016/j.nmd.2018.06.010. Epub 2018 Jul 2.

PMID:
30149909
5.

Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Washetine K, Heeke S, Bonnetaud C, Kara-Borni M, Ilié M, Lassalle S, Butori C, Long-Mira E, Marquette CH, Cohen C, Mouroux J, Selva E, Tanga V, Bence C, Félix JM, Gazoppi L, Skhiri T, Gormally E, Boucher P, Clément B, Dagher G, Hofman V, Hofman P.

Cancers (Basel). 2018 Jun 29;10(7). pii: E220. doi: 10.3390/cancers10070220.

6.

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Hofman V, Lassalle S, Bence C, Long-Mira E, Nahon-Estève S, Heeke S, Lespinet-Fabre V, Butori C, Ilié M, Hofman P.

Cancers (Basel). 2018 Mar 13;10(3). pii: E70. doi: 10.3390/cancers10030070. Review.

7.

Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France.

Leroy S, Benzaquen J, Mazzetta A, Marchand-Adam S, Padovani B, Israel-Biet D, Pison C, Chanez P, Cadranel J, Mazières J, Jounieaux V, Cohen C, Hofman V, Ilie M, Hofman P, Marquette CH; AIR Project Study Group.

BMJ Open. 2017 Dec 26;7(12):e018884. doi: 10.1136/bmjopen-2017-018884.

8.

Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer.

Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin JC, Tanga V, Washetine K, Long-Mira E, Maitre P, Yazbeck N, Bordone O, Lespinet V, Leroy S, Cohen C, Mouroux J, Marquette CH, Hofman V, Hofman P.

Oncotarget. 2017 Oct 4;8(61):103055-103062. doi: 10.18632/oncotarget.21476. eCollection 2017 Nov 28.

9.

MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma.

Bozec A, Zangari J, Butori-Pepino M, Ilie M, Lalvee S, Juhel T, Butori C, Brest P, Hofman P, Vouret-Craviari V.

Oncotarget. 2017 Jul 11;8(34):57174-57186. doi: 10.18632/oncotarget.19170. eCollection 2017 Aug 22.

10.

Erratum à l’article : « Immunohistochimie PD-1/PD-L1 en oncologie thoracique : où en sommes-nous ? » [Ann. Pathol. 37(1) (2017) 39–45].

Hofman P, Ilié M, Lassalle S, Long É, Coraline Bence, Butori C, Hofman V.

Ann Pathol. 2017 Aug;37(4):344. doi: 10.1016/j.annpat.2017.06.002. Epub 2017 Aug 1. French. No abstract available.

PMID:
28778623
11.

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients.

Ilie M, Szafer-Glusman E, Hofman V, Long-Mira E, Suttmann R, Darbonne W, Butori C, Lalvée S, Fayada J, Selva E, Yu W, Marquette CH, Shames DS, Punnoose E, Hofman P.

Oncotarget. 2017 Apr 18;8(16):26112-26121. doi: 10.18632/oncotarget.15345.

12.

[PD1/PD-L1 immunohistochemistry in thoracic oncology: Where are we?]

Hofman P, Ilié M, Lassalle S, Long E, Bence C, Butori C, Hofman V.

Ann Pathol. 2017 Feb;37(1):39-45. doi: 10.1016/j.annpat.2016.12.006. Epub 2017 Jan 31. French. Erratum in: Ann Pathol. 2017 Aug;37(4):344.

PMID:
28159404
13.

Fibronectin-guided migration of carcinoma collectives.

Gopal S, Veracini L, Grall D, Butori C, Schaub S, Audebert S, Camoin L, Baudelet E, Radwanska A, Beghelli-de la Forest Divonne S, Violette SM, Weinreb PH, Rekima S, Ilie M, Sudaka A, Hofman P, Van Obberghen-Schilling E.

Nat Commun. 2017 Jan 19;8:14105. doi: 10.1038/ncomms14105.

14.

PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.

Ilie M, Falk AT, Butori C, Chamorey E, Bonnetaud C, Long E, Lassalle S, Zahaf K, Vénissac N, Mouroux J, Cohen C, Brambilla E, Marquette CH, Hofman V, Hofman P.

Mod Pathol. 2016 Dec;29(12):1552-1564. doi: 10.1038/modpathol.2016.149. Epub 2016 Aug 26.

15.

MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.

Lassalle S, Zangari J, Popa A, Ilie M, Hofman V, Long E, Patey M, Tissier F, Belléannée G, Trouette H, Catargi B, Peyrottes I, Sadoul JL, Bordone O, Bonnetaud C, Butori C, Bozec A, Guevara N, Santini J, Hénaoui IS, Lemaire G, Blanck O, Vielh P, Barbry P, Mari B, Brest P, Hofman P.

Oncotarget. 2016 May 24;7(21):30461-78. doi: 10.18632/oncotarget.8458.

16.

High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness.

Long E, Ilie M, Bence C, Butori C, Selva E, Lalvée S, Bonnetaud C, Poissonnet G, Lacour JP, Bahadoran P, Brest P, Gilson E, Ballotti R, Hofman V, Hofman P.

Cancer Med. 2016 Jun;5(6):1022-30. doi: 10.1002/cam4.661. Epub 2016 Mar 6.

17.

[Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies].

Hofman V, Ilie M, Long E, Butori C, Lassalle S, Washetine K, Lalve S, Marquette CH, Soria JC, Hofman P.

Bull Cancer. 2016 Apr;103(4):368-80. doi: 10.1016/j.bulcan.2016.01.014. Epub 2016 Feb 23. Review. French.

PMID:
26920041
18.

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.

Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P.

J Am Acad Dermatol. 2015 May;72(5):786-93. doi: 10.1016/j.jaad.2015.01.012. Epub 2015 Feb 7.

PMID:
25659223
19.

Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps.

Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C, Selva E, Merino-Trigo A, Vénissac N, Mouroux J, Vrignaud P, Hofman P.

Cancer Med. 2015 Feb;4(2):201-11. doi: 10.1002/cam4.357. Epub 2014 Dec 3.

20.

[Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations].

Hofman V, Ilie M, Long E, Lassalle S, Butori C, Bence C, Washetine K, Lalvee S, Hofman P.

Bull Cancer. 2014 Oct;101(10):958-65. doi: 10.1684/bdc.2014.2041. Review. French.

PMID:
25373695

Supplemental Content

Loading ...
Support Center